Colorectal Cancer Clinical Trial
Official title:
Colorectal Cancer (CRC) Screening in Hong Kong: an Analysis on Acceptability, Compliance, Diagnostic Accuracy and Clinical Outcomes
Colorectal neoplasm in Asia is now increasingly common and is rising in an alarming manner in
Hong Kong. Population-based screening for colorectal cancer (CRC) should be implemented. With
the establishment of the CUHK JC Bowel Cancer Education Centre in 2008, about 10,000
asymptomatic subjects aged 50-70 years have completed screening by either faeca
immunochemical test (FIT)or colonoscopy till December 2012. From 2013 onwards, the centre
invites subjects aged 40-70 years with risk factors for CRC to undergo screening by FIT on a
yearly basis. If FIT result is positive, according to local practice, they will be offered a
routine colonoscopy as they will be treated as symptomatic. Currently, about 2,500 subjects
have received CRC screening in this new project. There will be 2,500 subjects more to be
recruited to this till 31 December 2017. The investigators would like to carry out a
prospective cohort study of these 2,500 subjects and also retrospectively review the cohort
of 12,500 subjects who received CRC screening in the CUHK JC Bowel Cancer Education Centre.
The present study aims to:
1. . Evaluate the knowledge, attitude, perception, practice, perceived obstacles and
changes in choice of CRC screening among the screening participants;
2. . Assess the levels of compliance across time among those who joined the screening
programme, according to different subject characteristics;
3. . Explore the diagnostic accuracy of faecal immunochemical tests among subjects with
different characteristics;
4. . Evaluate the risk factors for colorectal neoplasia and if applicable, devise and
validate a risk scoring system for prediction of neoplasia in different colon sites;
5. . Evaluate the association between bowel preparation, colonoscopy withdrawal time and
adenoma detection rate among those who received colonoscopy;
6. . Validation of the existing risk scoring systems for colorectal neoplasia from the
literature, based on findings from subjects who received colonoscopy.
7. . Explore potential associations among colorectal neoplasia detected in different colon
sites.
BACKGROUND
Colorectal neoplasm in Asia is not less common compared to that of the Western population and
screening for colorectal cancer (CRC) should be implemented. In the Asia Pacific Consensus
for Colorectal Cancer, Fecal Occult Blood Test (FOBT) was recommended as the preferred test
in resource limited areas in Asia. Yet, the preference of Asian in the options for CRC
screening might be different. In a recent study from Hong Kong, most subjects preferred to
use colonoscopy instead of stool tests as the screening tool.
A study from Asia showed that fecal immunochemical test (FIT) might be preferred because it
obviates the need for dietary control. Educating the public about different options available
is an important method to change the health seeking behavior of subjects. The CUHK JC Bowel
Cancer Education Centre was established in 2008 with full funding from the Hong Kong Jockey
Club Charities Trust. About 10,000 subjects received CRC screening by either FIT or
colonoscopy till 31 December 2012. From 2013 onwards, the centre invites subjects aged 40-70
years with risk factors for CRC to undergo screening by FIT on a yearly basis. If FIT result
is positive, according to local practice, they will be offered a routine colonoscopy as they
will be treated as symptomatic. Currently, a total of about 2,500 asymptomatic subjects have
received CRC screening in this new project and the Centre will continue to recruit 2,500
subjects more till 31 December 2017.
To inform future screening policy for implementation of population-based screening, it is
important to explore the different aspects of this community-based CRC screening programme
which include various indicators of programmatic performance.
STUDY AIMS
1. Evaluate the knowledge, attitude, perception, practice, perceived obstacles and changes
in choice of CRC screening among the screening participants;
2. Assess the levels of compliance across time among those who joined the screening
programme, according to different subject characteristics;
3. Explore the diagnostic accuracy of faecal immunochemical tests among subjects with
different characteristics;
4. Evaluate the risk factors for colorectal neoplasia and if applicable, devise and
validate a risk scoring system for prediction of neoplasia in different colon sites;
5. Evaluate the association between bowel preparation, colonoscopy withdrawal time and
adenoma detection rate among those who received colonoscopy;
6. Validation of the existing risk scoring systems for colorectal neoplasia from the
literature, based on findings from subjects who received colonoscopy.
7. Explore potential associations among colorectal neoplasia detected in different colon
sites.
METHODOLOGY
Retrospective cohort Demographic data, health behavior information and clinical outcomes of
subjects who received CRC screening in CUHK Bowel Cancer Education Centre from December 2008
to Sept 2015 will be retrospectively reviewed without consent and analyzed.
Prospective cohort
1. Study subjects will be invited to join the study via routine health talk of a CRC
screening program organized by CUHK JC Bowel Cancer Education Centre
2. Each eligible subject completed a self-administered survey, which consists of
sociodemographic information, family history of CRC for a first-degree relative, past
medical history, and use of chronic medications. The completeness of questionnaires is
checked afterwards. Trained volunteers assist survey completion for the relatively
illiterate participants. The investigators used a quantitative FIT (OC Sensor).
Participants received information on procedures for collecting the FIT samples at home,
according to the manufacturer's instructions. They are requested to return their
collection tubes containing faecal specimens to the centre 6 days within the stool
collection. For those with negative FIT, they will be reminded to continue the FIT
screening on a yearly basis till 2018. For those subjects with FIT positive findings,
according to local practice, they will be offered a routine colonoscopy as they will be
treated as symptomatic. Subjects who undergo colonoscopy may receive a phone-call follow
up every year for the period of the study to monitor the clinical outcome of the
subject. Subjects develop symptoms suggestive of colorectal neoplasm will be worked up
by the original team of investigators.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Not yet recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |